Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Celgene Q2 Tops Estimates, Lifts Earnings Forecast - Quick Facts

RELATED NEWS
Trade CELG now with 
7/26/2012 7:57 AM ET

Drug maker Celgene Corp. (CELG: Quote) reported Thursday better-than-expected earnings and revenues for its second quarter benefited by strong volume growth. The company also lifted its fiscal 2012 earnings forecast, while backed revenue view.

Second-quarter net income attributable to the company increased to $367.37 million or $0.82 per share from last year's $279.40 million or $0.59 per share. Adjusted earnings, which excluded certain items, climbed 31 percent to $545 million and earnings per share increased 37 percent to $1.22 from $0.89 last year.

On average, 24 analysts polled by Thomson Reuters expected earnings of $1.18 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter climbed 16 percent to $1.37 billion from prior year's $1.18 billion, while analysts were looking for revenues of $1.35 billion.

Net product sales increased 16 percent, reflecting strong volume growth in the U.S., Europe and Japan. U.S. and international net product sales increased 15 percent and 19 percent, respectively.

Bob Hugin, Chairman and Chief Executive Officer, said, "The second quarter financial results were very strong and provide significant momentum for the second half of the year. The recent positive apremilast phase III data is the first of multiple pivotal trial results and regulatory actions across our portfolio anticipated through early 2013."

Looking ahead, the company now expects fiscal 2012 earnings per share to increase about 31 percent to a range of $3.69 to $3.80, compared to previous range of $3.52 to $3.67 per share. Adjusted earnings is now expected to increase approximately 27 percent year-over-year to a range of $4.80 to $4.85, up from a previous range of $4.70 to $4.80.

Meanwhile, the company continues to expect adjusted total revenue to increase approximately 15 percent to a range of $5.4 billion to $5.6 billion.

Analysts expect earnings of $4.80 per share on revenues of $5.45 billion.

Register
To receive FREE breaking news email alerts for Celgene Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
There was a mixed performance on Wall Street on Friday. Shares suffered an early decline, as investors continued to express worries about the Federal Reserve. A recovery through the rest of the day allowed the Dow to edge into positive territory by the close. The Nasdaq and S&P 500 posted fractional losses. Stocks have shown a notable move to the downside in early trading on Friday amid lingering concerns about the outlook for the Federal Reserve's asset purchase program. The major averages have slid firmly into negative territory, adding to the modest losses posted in the previous session. The major averages are currently posting notable losses, near their lows for the young session. After reporting a sharp drop in new orders for manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than anticipated in the month of April. The report said durable goods orders surged up by 3.3 percent in April after tumbling by a revised 5.9 percent in March.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.